In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.
Tuesday, November 10
European Commission Expands Melflufen Label to Third-Line Multiple MyelomaCancerNetwork (EUA) · 17:38 Acesso e saúde públicaEUAData from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
Gilead at Wolfe Healthcare Conference: anito-cel launch in focus By Investing.comInvesting.com India (EUA) · 17:07 TratamentosEUA
T-cell engager Shows Early Activity in Relapsed Multiple MyelomaEMJ (Reino Unido) · 09:05 InvestigaçãoReino UnidoPhase 1 findings support further study of MK-4002 in relapsed multiple myeloma, with early responses balanced against frequent severe adverse events.
Monday, November 9th
Melflufen Gains EU Expansion in Third-Line Lenalidomide-Refractory Multiple MyelomaOncLive (EUA) · 21:41 TratamentosEUAThe decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and DexamethasoneASCO Publications (Reino Unido) · 21:20 Doentes e associaçõesReino Unido
Published American recommendations for the management of renal transplantation in patients with plasmacytic disorders.InternationalMy Hematologia · 5 Sep 2025This article discusses how kidney transplantation can be an option for people with multiple myeloma and other diseases that damage the kidneys, but it still presents challenges. Read more →
Diagnosis of Multiple Myeloma Through an Atypical Serum Protein Electrophoresis Profile: A Case ReportCureus (EUA) · 20:01 OutrasEUA
Under-the-skin myeloma treatment linked to better survival in studyRare Cancer News (Reino Unido) · 15:10 Doentes e associaçõesReino UnidoDarzalex Faspro was linked to better survival than IV Darzalex in people with multiple myeloma, according to a Medicare data analysis.
BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R MyelomaOncLive (EUA) · 14:06 TratamentosEUADuring a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
European Commission Expands Melphalan Flufenamide Approval to Third-Line Treatment for Multiple MyelomaOncodaily · 12:52 Acesso e saúde públicaEuropean Commission Expands Melphalan Flufenamide Approval to Third-Line Treatment for Multiple Myeloma / dexamethasone, Drug Approval, EMA, European
Myeloma fund launches with £15m initial backingPharmaTimes (Reino Unido) · 10:44 Acesso e saúde públicaReino UnidoPhilanthropy initiative targets treatment innovation
Friday, November 6th
New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026News-Medical (Internacional) · 08:00 InvestigaçãoInternacionalOncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that two abstracts highlighting real-world clinical outcomes for Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society…
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAIDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
Wednesday, 11/04
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)Karyopharm (EUA) · 14:04 Doentes e associaçõesEUA– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026...
Treatment After Early Relapse and Real-World Evidence in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel discusses treatment strategies for patients with relapsed/refractory multiple myeloma who experience early disease progression following BCMA-directed therapy, including CAR T-cell therapy.
Myeloma's Gray Zones: Sequencing, Oral Therapy, and FrailtyOncology Nursing News (EUA) · 08:00 Acesso e saúde públicaEUAAt the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.
Emerging Therapies and Supportive Care Advances in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel looks ahead to emerging developments that may continue to shape treatment of relapsed/refractory multiple myeloma.
CD38-Targeted Immuno-PET Helps Detect Active Multiple MyelomaCancerNetwork (EUA) · 08:00 Doentes e associaçõesEUAIn a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Modern rises 8% on early multiple myeloma data for its three-in-one mRNA therapy.TIKR.com · 08:00 TreatmentsPTSmall trial, big idea.
